Fulgent Genetics (NASDAQ:FLGT) Trading Up 5.5%

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report)'s stock price traded up 5.5% during trading on Monday . The company traded as high as $22.68 and last traded at $22.68. 30,821 shares changed hands during trading, a decline of 84% from the average session volume of 198,101 shares. The stock had previously closed at $21.50.

Analyst Ratings Changes

Separately, Piper Sandler lowered their target price on shares of Fulgent Genetics from $28.00 to $25.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 6th.

Fulgent Genetics Trading Down 0.0 %

The company has a 50 day moving average of $21.71 and a 200 day moving average of $24.95. The firm has a market cap of $642.55 million, a price-to-earnings ratio of -3.86 and a beta of 1.43.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.61. Fulgent Genetics had a negative net margin of 57.72% and a negative return on equity of 2.92%. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $67.14 million. As a group, sell-side analysts anticipate that Fulgent Genetics, Inc. will post -2.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of FLGT. Dimensional Fund Advisors LP raised its position in Fulgent Genetics by 11.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company's stock valued at $41,839,000 after purchasing an additional 147,505 shares during the last quarter. Park West Asset Management LLC raised its holdings in Fulgent Genetics by 23.1% during the 4th quarter. Park West Asset Management LLC now owns 424,783 shares of the company's stock worth $12,280,000 after purchasing an additional 79,649 shares during the last quarter. Invesco Ltd. lifted its position in Fulgent Genetics by 150.3% during the 3rd quarter. Invesco Ltd. now owns 312,627 shares of the company's stock valued at $8,360,000 after purchasing an additional 187,717 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Fulgent Genetics by 14.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 267,313 shares of the company's stock valued at $7,728,000 after purchasing an additional 33,141 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Fulgent Genetics by 9.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 103,382 shares of the company's stock worth $2,764,000 after buying an additional 8,601 shares during the period. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.